Table 2 Outcomes after pair-matched analysis in ATG and PTCY group.

From: Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor

 

ATG group (95% CI)

PTCY group (95% CI)

P-value

1-year OS (%)

62 (52–71)

55 (39–69)

0.70

1-year PFS (%)

57 (47–66)

50 (34–64)

0.74

1-year NRM (%)

22 (15–30)

34 (20–49)

0.12

1-year RI (%)

21 (14–30)

16 (7–29)

0.19

Neutrophile engraftment at day +30 (%)

97 (91–99)

100

0.09

Grade II-IV aGVHD at day +100 (%)

26 (18–35)

41 (28–54)

0.08

Grade III-IV aGVHD at day +100 (%)

11 (6–18)

15.7 (7.3–27)

0.68

cGVHD at 1 year (%)

29 (20–38)

20 (9–34)

0.51

Extensive cGVHD at 1 year (%)

19 (11–27)

5 (1–15)

0.06

1-year GFRS (%)

41 (31–50)

47 (31–61)

0.68

  1. ATG antithymocyte globuline, PTCY post-transplant cyclophosphamide, 95% CI 95% confidence interval, OS overall survival, PFS Progression-free survival, NRM non-relapse mortality, RI Relapse incidence, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, GFRS graft-versus-host disease-free, relapse-free survival.
Back to article page